What are the key takeaways for Cosmos Health Inc ($COSM)?

Net loss widened to $6,086,500 with diluted EPS of -$0.10 for Q2 2026, as gross profits of $1,518,912 failed to absorb operating overhead. Severe liquidity constraint with cash balances of $1,801,000 against total debt of $15,338,600 and quarterly free cash burn of -$1,800,900 as of June 30, 2026. Revenue grew 28.8% YoY to $18,986,400 in Q2 2026, driven by higher wholesale pharmaceutical volumes in European markets.

Cosmos Health Inc (COSM) AI Stock Analysis & Earnings

Please enable JavaScript to continue using this application.

Latest Report Overview for Cosmos Health Inc ($COSM)

AI-powered analysis of Cosmos Health Inc (COSM) stock based on Q2 2026 financial data.

Published: October 18, 2026

Latest Report Overview

Cosmos Health Inc (COSM) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q2 FY2026) revenue of $19 million with diluted EPS of $-0.10 and net income of -$6.1 million. Operating margin was -15.4%, and free cash flow was -$1.8 million for the period. Operating performance continued to face significant structural pressure as operating losses widened to -$2,923,900, translating to an operating margin of -15.4%. Research and development expense was limited to $68,600, while stock-based compensation totaled $558,900. Net margins remained deeply negative at -32.1%, driven by operating overhead and debt service costs that outstripped gross profit generation. Cash and cash equivalents ended the period at $1,801,000, while total outstanding debt stood at $15,338,600, generating net debt of $13,537,600. Operating cash flow for the quarter was -$1,718,300, leading to a quarterly free cash flow burn of -$1,800,900 and bringing trailing twelve-month free cash flow deficits to -$9,951,300. The company remains focused on optimizing working capital and exploring non-dilutive liquidity alternatives. Management continues to prioritize the commercial expansion of its proprietary nutraceutical and wellness portfolio, targeting retail pharmacy chains across Europe and North America to diversify away from thin-margin wholesale distribution. Strategic initiatives also include expanding contract manufacturing at European GMP-certified facilities and exploring digital health partnerships.

Key Takeaways for Cosmos Health Inc

Net loss widened to $6,086,500 with diluted EPS of -$0.10 for Q2 2026, as gross profits of $1,518,912 failed to absorb operating overhead.
Severe liquidity constraint with cash balances of $1,801,000 against total debt of $15,338,600 and quarterly free cash burn of -$1,800,900 as of June 30, 2026.
Revenue grew 28.8% YoY to $18,986,400 in Q2 2026, driven by higher wholesale pharmaceutical volumes in European markets.
Gross margin contracted to 8.0% from 15.2% in Q3 2025, demonstrating severe pricing pressure in core distribution operations.
Persistent operating cash outflows of -$1,718,300 underscore continued reliance on external financing and potential equity dilution.
Commercialization of proprietary nutraceutical lines such as Sky Premium Life remains essential to achieving gross margin inflection.

What Does Cosmos Health Inc Do?

Cosmos Health Inc. is an international healthcare group operating across two primary business activities: wholesale pharmaceutical distribution and the development, manufacturing, and commercialization of proprietary health and wellness products. In its distribution business, the company supplies branded and generic pharmaceuticals, over-the-counter (OTC) medications, medical devices, and food supplements to independent retail pharmacies, hospital networks, and secondary wholesalers. Core operating subsidiaries include Doc Pharma S.A. in Greece and Decahedron Ltd in the United Kingdom. In its proprietary brand segment, Cosmos Health manufactures and markets branded nutraceuticals, food supplements, and skincare formulations under proprietary banners including Sky Premium Life, Mediterranation, and Bio-bebe. The company operates European Union Good Manufacturing Practice (GMP) certified manufacturing facilities, providing in-house production capabilities as well as third-party contract manufacturing services. Customers span retail pharmacies, digital e-commerce channels, and regional distributors in Europe, North America, and select international markets. Cosmos Health operates across key European hubs in Greece and the UK, with corporate administrative operations in Chicago, Illinois. For the trailing twelve months ended June 30, 2026, the company generated $73,727,900 in total revenue. Its business model seeks to combine the broad logistics reach and retail pharmacy access of wholesale distribution with the superior gross margins of proprietary wellness formulations.

Growth Drivers for Cosmos Health Inc

International commercial expansion of Sky Premium Life and Mediterranation nutraceutical lines into North American and Middle Eastern retail and online channels.
Expansion of wholesale distribution coverage and hospital supply contracts across independent pharmacy networks in the United Kingdom via Decahedron Ltd.
Scaling third-party contract manufacturing and private-label packaging at European Union GMP-certified production facilities.
Introduction of new specialized formulation stock-keeping units (SKUs) in functional health, sports nutrition, and preventive wellness.
Strategic exploration of digital health, telemedicine, and personalized health screening tools to create supplementary service revenue.

Overview AI Summary Charts Financials Valuation

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Cosmos Health Inc ($COSM)

Key Takeaways

1.Net loss widened to $6,086,500 with diluted EPS of -$0.10 for Q2 2026, as gross profits of $1,518,912 failed to absorb operating overhead.
2.Severe liquidity constraint with cash balances of $1,801,000 against total debt of $15,338,600 and quarterly free cash burn of -$1,800,900 as of June 30, 2026.
3.Revenue grew 28.8% YoY to $18,986,400 in Q2 2026, driven by higher wholesale pharmaceutical volumes in European markets.
4.Gross margin contracted to 8.0% from 15.2% in Q3 2025, demonstrating severe pricing pressure in core distribution operations.
5.Persistent operating cash outflows of -$1,718,300 underscore continued reliance on external financing and potential equity dilution.
6.Commercialization of proprietary nutraceutical lines such as Sky Premium Life remains essential to achieving gross margin inflection.

What They Do

How They Make Money

Cosmos Health generates revenue predominantly through point-of-sale wholesale transactions and commercial product deliveries. Revenue is recognized when performance obligations are satisfied upon the transfer of control of goods to customers, typically upon shipment or physical delivery depending on contractual shipping terms. The vast majority of sales are transactional rather than contractual recurring revenue, with contractual subscriptions or licensing representing under 30% of total receipts. Wholesale pharmaceutical distribution constitutes approximately 85% to 90% of total revenue. This revenue stream is characterized by high transaction volumes, rapid inventory turnover, and very thin gross profit margins, typically ranging from 6% to 10%. Revenue in this segment is driven by order volume from community pharmacy networks, hospital tenders, and wholesale fulfillment contracts across Greece and the United Kingdom. The proprietary brand and contract manufacturing segment accounts for the remaining 10% to 15% of revenue. This stream encompasses sales of proprietary nutraceuticals (Sky Premium Life and Mediterranation) and third-party contract manufacturing. This segment commands structurally higher gross margins (often 30% to 50%), though revenue growth depends heavily on distributor onboarding, retail shelf space acquisition, and direct-to-consumer digital marketing effectiveness.

Competitive Position

In wholesale pharmaceutical distribution, Cosmos Health competes against entrenched multi-billion-dollar global distributors including Cencora (formerly AmerisourceBergen), Phoenix Group, and McKesson Europe, as well as established national pharmaceutical cooperatives across Greece and the UK. These industry incumbents possess unmatched purchasing power, sophisticated automated logistics hubs, and deeply embedded credit relationships with pharmacy networks, placing Cosmos Health at a structural cost and scale disadvantage. In the nutraceutical and wellness category, the company competes with international brand conglomerates such as Nestlé Health Science, Haleon, Herbalife, and Nature's Bounty, alongside hundreds of specialized supplement brands. Cosmos Health differentiates through proprietary formulations, Mediterranean-sourced natural ingredients, and European GMP manufacturing certification. However, the supplement sector has low barriers to entry and intense marketing-driven customer acquisition dynamics. Financially, Cosmos Health trades at compressed multiples (P/S of 0.5x, EV/Sales of 0.6x) relative to scaled healthcare peers, reflecting an EBITDA margin of -22.8%, an operating margin of -15.4%, and recurring free cash flow deficits. The company's low gross margin of 8.0% in Q2 2026 highlights minimal pricing power in wholesale distribution, where pharmacies can easily substitute distributors based on product availability and credit terms. While the company's dual model theoretically offers cross-selling opportunities into retail pharmacies, its competitive durability is fragile. Without substantial capital to invest in automated distribution infrastructure or massive consumer brand campaigns, Cosmos Health remains vulnerable to scale advantages of major logistics rivals and brand equity of established wellness leaders.

Business Strategy & Moat

Cosmos Health's strategic framework relies on a hybrid distribution and proprietary brand flywheel. The strategic logic entails utilizing its wholesale distribution infrastructure and daily delivery routes to secure relationships with thousands of community pharmacies, subsequently leveraging that distribution pipeline to introduce higher-margin proprietary nutraceutical brands without incurring prohibitive third-party distribution fees. Manufacturing these products in-house at owned European GMP facilities is intended to capture full supply chain margins. However, switching costs across the company's core distribution customer base are low. Pharmacies regularly purchase from multiple wholesalers based on real-time drug availability, statutory discounts, and payment terms, leaving Cosmos Health with negligible pricing power. In the proprietary brand segment, consumer brand loyalty is moderate, requiring sustained promotional and marketing expenditures to defend retail shelf space. Capital allocation has been strained by operational cash burn. Rather than funding robust internal R&D—which totaled just $68,600 in Q2 2026—capital has been directed toward servicing $15,338,600 in outstanding debt and covering operating cash deficits. Management has historically utilized debt and dilutive equity issuance to finance acquisitions such as Decahedron and Doc Pharma. The moat remains narrow and structurally weak, as demonstrated by persistent negative return on invested capital (-63.4%) and negative operating margins.

Industry Outlook

The European pharmaceutical wholesale and distribution sector operates within a highly regulated, low-margin environment. Wholesalers are subject to rigorous Good Distribution Practice (GDP) standards, serialized tracking mandates, and national government price controls on prescription pharmaceuticals. While aging populations and rising chronic disease prevalence provide steady baseline volume growth of 3% to 5% annually, escalating logistics costs, refrigerated transport requirements, and strict regulatory compliance impose structural margin headwinds on mid-sized operators. Conversely, the global nutraceutical and dietary supplement industry exhibits stronger secular growth, expanding at an estimated 7% to 9% CAGR driven by proactive consumer health consciousness, preventive wellness spending, and aging demographic trends. However, inflationary pressures on discretionary consumer budgets and rising digital advertising costs have increased customer acquisition expenses for wellness brands across Europe and the United States. Regulatory scrutiny is intensifying across European healthcare markets, particularly concerning product labeling claims, ingredient safety, and supply chain resilience for essential medicines. Mid-sized distributors like Cosmos Health must continually navigate compliance with European Medicines Agency (EMA) and UK MHRA frameworks, where non-compliance can lead to severe operational disruptions or license suspensions.

Growth Drivers

•International commercial expansion of Sky Premium Life and Mediterranation nutraceutical lines into North American and Middle Eastern retail and online channels.
•Expansion of wholesale distribution coverage and hospital supply contracts across independent pharmacy networks in the United Kingdom via Decahedron Ltd.
•Scaling third-party contract manufacturing and private-label packaging at European Union GMP-certified production facilities.
•Introduction of new specialized formulation stock-keeping units (SKUs) in functional health, sports nutrition, and preventive wellness.
•Strategic exploration of digital health, telemedicine, and personalized health screening tools to create supplementary service revenue.

Recent Developments

•Reported Q2 2026 financial results on August 18, 2026, delivering revenue of $18,986,400 (+28.8% YoY) alongside a net loss of $6,086,500.
•Managed total outstanding debt obligations to $15,338,600 as of June 30, 2026, compared to $16,752,700 in the preceding quarter.
•Secured expanded retail and e-commerce distribution agreements in May 2026 for the Sky Premium Life nutraceutical portfolio across selected European territories.
•Advanced cross-border supply chain integration between Greek distribution operations (Doc Pharma) and UK wholesale networks (Decahedron) during Q2 2026.
•Continued executing capital preservation and equity compliance initiatives throughout the first half of 2026 to satisfy NASDAQ continued listing standards.

Catalysts

•Filing and disclosure of Q3 2026 financial results to evaluate whether gross margins recover from the 8.0% level recorded in Q2 2026.
•Potential debt refinancing or debt maturity extension announcements regarding the company's $15,338,600 in total debt obligations.
•Commercial launch milestones and pharmacy re-order rates for proprietary nutraceutical brands across international retail accounts.
•Regulatory updates or formal notifications regarding NASDAQ compliance regarding stockholders' equity and minimum bid price thresholds.

Acquisitions & Strategy

•Acquired Decahedron Ltd in October 2022 to expand wholesale pharmaceutical distribution capabilities into the United Kingdom market.
•Acquired Doc Pharma S.A. to establish a core pharmaceutical distribution and generic drug distribution network in Greece and Southeastern Europe.
•Acquired CosmoLabs in December 2021 to secure owned European GMP-certified manufacturing facilities for liquid and solid dosage health formulations.

Share Repurchase / Buyback Program

•No active share repurchase program was conducted during the quarterly period ended June 30, 2026, as available liquidity was allocated to operations and debt service.

RPO & Key Performance Indicators

•Quarterly revenue grew 28.8% YoY to $18,986,400 in Q2 2026, while trailing twelve-month revenue reached $73,727,900 (+33.82% YoY).
•Gross margin was 8.0% in Q2 2026, compressing from 10.6% in Q4 2025 and 15.2% in Q3 2025.
•Operating cash flow remained negative at -$1,718,300 for Q2 2026, contributing to trailing twelve-month free cash flow burn of -$9,951,300.

Strengths

•Demonstrated top-line revenue momentum with Q2 2026 revenue increasing 28.8% YoY to $18,986,400 on strong wholesale shipment volume.
•Established distribution network providing direct access to thousands of independent pharmacies across Greece and the United Kingdom.
•Ownership of European Union GMP-certified manufacturing facilities offering vertical integration and contract manufacturing capacity.
•Portfolio of proprietary wellness brands including Sky Premium Life that provides an avenue for structural margin enhancement.
•Active founder-led executive leadership maintaining deep supplier relationships across Southeastern European pharmaceutical markets.

AI Benefits & Opportunities

•Potential deployment of AI-enabled route optimization and inventory demand forecasting to decrease logistics costs across European pharmaceutical distribution routes.
•Opportunity to utilize machine learning algorithms to personalize direct-to-consumer nutraceutical product recommendations on digital e-commerce storefronts.

Risks & Concerns for Cosmos Health Inc ($COSM)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Cosmos Health Inc (COSM, filings period ending June 30, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Oct 18, 2026.

Based on June 30, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Cosmos Health Inc ($COSM)

Key Takeaways

1.Net loss widened to $6,086,500 with diluted EPS of -$0.10 for Q2 2026, as gross profits of $1,518,912 failed to absorb operating overhead.
2.Severe liquidity constraint with cash balances of $1,801,000 against total debt of $15,338,600 and quarterly free cash burn of -$1,800,900 as of June 30, 2026.
3.Revenue grew 28.8% YoY to $18,986,400 in Q2 2026, driven by higher wholesale pharmaceutical volumes in European markets.
4.Gross margin contracted to 8.0% from 15.2% in Q3 2025, demonstrating severe pricing pressure in core distribution operations.
5.Persistent operating cash outflows of -$1,718,300 underscore continued reliance on external financing and potential equity dilution.
6.Commercialization of proprietary nutraceutical lines such as Sky Premium Life remains essential to achieving gross margin inflection.

What They Do

How They Make Money

Competitive Position

Business Strategy & Moat

Industry Outlook

Growth Drivers

•International commercial expansion of Sky Premium Life and Mediterranation nutraceutical lines into North American and Middle Eastern retail and online channels.
•Expansion of wholesale distribution coverage and hospital supply contracts across independent pharmacy networks in the United Kingdom via Decahedron Ltd.
•Scaling third-party contract manufacturing and private-label packaging at European Union GMP-certified production facilities.
•Introduction of new specialized formulation stock-keeping units (SKUs) in functional health, sports nutrition, and preventive wellness.
•Strategic exploration of digital health, telemedicine, and personalized health screening tools to create supplementary service revenue.

Recent Developments

•Reported Q2 2026 financial results on August 18, 2026, delivering revenue of $18,986,400 (+28.8% YoY) alongside a net loss of $6,086,500.
•Managed total outstanding debt obligations to $15,338,600 as of June 30, 2026, compared to $16,752,700 in the preceding quarter.
•Secured expanded retail and e-commerce distribution agreements in May 2026 for the Sky Premium Life nutraceutical portfolio across selected European territories.
•Advanced cross-border supply chain integration between Greek distribution operations (Doc Pharma) and UK wholesale networks (Decahedron) during Q2 2026.
•Continued executing capital preservation and equity compliance initiatives throughout the first half of 2026 to satisfy NASDAQ continued listing standards.

Catalysts

•Filing and disclosure of Q3 2026 financial results to evaluate whether gross margins recover from the 8.0% level recorded in Q2 2026.
•Potential debt refinancing or debt maturity extension announcements regarding the company's $15,338,600 in total debt obligations.
•Commercial launch milestones and pharmacy re-order rates for proprietary nutraceutical brands across international retail accounts.
•Regulatory updates or formal notifications regarding NASDAQ compliance regarding stockholders' equity and minimum bid price thresholds.

Acquisitions & Strategy

•Acquired Decahedron Ltd in October 2022 to expand wholesale pharmaceutical distribution capabilities into the United Kingdom market.
•Acquired Doc Pharma S.A. to establish a core pharmaceutical distribution and generic drug distribution network in Greece and Southeastern Europe.
•Acquired CosmoLabs in December 2021 to secure owned European GMP-certified manufacturing facilities for liquid and solid dosage health formulations.

Share Repurchase / Buyback Program

•No active share repurchase program was conducted during the quarterly period ended June 30, 2026, as available liquidity was allocated to operations and debt service.

RPO & Key Performance Indicators

•Quarterly revenue grew 28.8% YoY to $18,986,400 in Q2 2026, while trailing twelve-month revenue reached $73,727,900 (+33.82% YoY).
•Gross margin was 8.0% in Q2 2026, compressing from 10.6% in Q4 2025 and 15.2% in Q3 2025.
•Operating cash flow remained negative at -$1,718,300 for Q2 2026, contributing to trailing twelve-month free cash flow burn of -$9,951,300.

Strengths

•Demonstrated top-line revenue momentum with Q2 2026 revenue increasing 28.8% YoY to $18,986,400 on strong wholesale shipment volume.
•Established distribution network providing direct access to thousands of independent pharmacies across Greece and the United Kingdom.
•Ownership of European Union GMP-certified manufacturing facilities offering vertical integration and contract manufacturing capacity.
•Portfolio of proprietary wellness brands including Sky Premium Life that provides an avenue for structural margin enhancement.
•Active founder-led executive leadership maintaining deep supplier relationships across Southeastern European pharmaceutical markets.

AI Benefits & Opportunities

•Potential deployment of AI-enabled route optimization and inventory demand forecasting to decrease logistics costs across European pharmaceutical distribution routes.
•Opportunity to utilize machine learning algorithms to personalize direct-to-consumer nutraceutical product recommendations on digital e-commerce storefronts.

Risks & Concerns for Cosmos Health Inc ($COSM)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

Summary generated on Oct 18, 2026.

Latest Report Overview for Cosmos Health Inc ($COSM)

AI-powered analysis of Cosmos Health Inc (COSM) stock based on Q2 2026 financial data.

Published: October 18, 2026

Latest Report Overview

Key Takeaways for Cosmos Health Inc

Net loss widened to $6,086,500 with diluted EPS of -$0.10 for Q2 2026, as gross profits of $1,518,912 failed to absorb operating overhead.
Severe liquidity constraint with cash balances of $1,801,000 against total debt of $15,338,600 and quarterly free cash burn of -$1,800,900 as of June 30, 2026.
Revenue grew 28.8% YoY to $18,986,400 in Q2 2026, driven by higher wholesale pharmaceutical volumes in European markets.
Gross margin contracted to 8.0% from 15.2% in Q3 2025, demonstrating severe pricing pressure in core distribution operations.
Persistent operating cash outflows of -$1,718,300 underscore continued reliance on external financing and potential equity dilution.
Commercialization of proprietary nutraceutical lines such as Sky Premium Life remains essential to achieving gross margin inflection.

What Does Cosmos Health Inc Do?

Growth Drivers for Cosmos Health Inc

International commercial expansion of Sky Premium Life and Mediterranation nutraceutical lines into North American and Middle Eastern retail and online channels.
Expansion of wholesale distribution coverage and hospital supply contracts across independent pharmacy networks in the United Kingdom via Decahedron Ltd.
Scaling third-party contract manufacturing and private-label packaging at European Union GMP-certified production facilities.
Introduction of new specialized formulation stock-keeping units (SKUs) in functional health, sports nutrition, and preventive wellness.
Strategic exploration of digital health, telemedicine, and personalized health screening tools to create supplementary service revenue.

Cosmos Health Inc (COSM) AI Stock Analysis & Earnings